{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T22:03:52Z","timestamp":1791669832296,"version":"4.3.4"},"reference-count":100,"publisher":"The Endocrine Society","issue":"7","license":[{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100012264","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012264","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020414","name":"NSF","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020414","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007028","name":"The Leona M. and Harry B. Helmsley Charitable Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007028","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015769","name":"Dexcom","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015769","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Diabetes is one of the most prevalent chronic diseases worldwide, with rates that continue to increase. More than 30 years ago, the Diabetes Control and Complications Trial demonstrated that intensive glucose management decreased long-term vascular complications. Unfortunately, many people with diabetes still struggle to meet glycemic goals. In this mini-review, we highlight advances in diabetes technology that are associated with improvements in glycemic management. Continuous glucose monitoring (CGM) and automated insulin delivery systems are associated with significant improvements in glycated hemoglobin (HbA1c), time in range (70-180 mg\/dL), and decreases in severe hypoglycemia and diabetic ketoacidosis in people with both type 1 and type 2 diabetes. Recent data show that these technologies improve outcomes early in the course of type 1 diabetes. CGM is also being explored as a tool to monitor progression through early-stage type 1 diabetes (2 antibodies positive) to identify individuals who may benefit from disease-modifying therapies as well as to prevent the onset of diabetic ketoacidosis at onset of stage 3 (insulin-requiring) type 1 diabetes. Adjunctive pharmacologic therapies and artificial intelligence may further expand and improve therapies, offering potential synergistic benefits. However, there continue to be significant disparities in access to diabetes technologies and access to insulin worldwide. This mini-review summarizes recently published data, highlights emerging applications, and underscores the need to pair technological innovation with strategies that promote equitable access and support for diabetes care to improve outcomes for all people with diabetes.<\/jats:p>","DOI":"10.1210\/clinem\/dgag164","type":"journal-article","created":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T19:07:45Z","timestamp":1776107265000},"page":"e1739-e1748","source":"Crossref","is-referenced-by-count":3,"title":["Diabetes technology: an update"],"prefix":"10.1210","volume":"111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9374-8469","authenticated-orcid":false,"given":"Priya","family":"Prahalad","sequence":"first","affiliation":[{"name":"Division of Pediatric Endocrinology, Department of Pediatrics, Stanford University , Stanford, CA 94304 ,","place":["USA"]},{"name":"Stanford Diabetes Research Center, Stanford University , Stanford, CA 94304 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dessi","family":"Zaharieva","sequence":"additional","affiliation":[{"name":"Division of Pediatric Endocrinology, Department of Pediatrics, Stanford University , Stanford, CA 94304 ,","place":["USA"]},{"name":"Stanford Diabetes Research Center, Stanford University , Stanford, CA 94304 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4602-7909","authenticated-orcid":false,"given":"David M","family":"Maahs","sequence":"additional","affiliation":[{"name":"Division of Pediatric Endocrinology, Department of Pediatrics, Stanford University , Stanford, CA 94304 ,","place":["USA"]},{"name":"Stanford Diabetes Research Center, Stanford University , Stanford, CA 94304 ,","place":["USA"]},{"name":"Department of Health Research and Policy (Epidemiology), Stanford University , Stanford, CA 94305 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2026,4,13]]},"reference":[{"key":"2026061619571680200_dgag164-B1","volume-title":"Data from: IDF Diabetes Atlas","author":"The International Diabetes Federation","year":"2025","edition":"11th ed"},{"key":"2026061619571680200_dgag164-B2","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2025.112277","article-title":"Global type 1 diabetes prevalence, incidence, and mortality estimates 2025: results from the International diabetes Federation Atlas, 11th edition, and the T1D index version 3.0","volume":"225","author":"Ogle","year":"2025","journal-title":"Diabetes Res Clin Pract"},{"issue":"14","key":"2026061619571680200_dgag164-B3","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJM199309303291401","article-title":"The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus","volume":"329","author":"Diabetes Control and Complications Trial Research Group","year":"1993","journal-title":"N Engl J Med"},{"issue":"1","key":"2026061619571680200_dgag164-B4","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S2213-8587(24)00279-1","article-title":"Treatment regimens and glycaemic outcomes in more than 100 000 children with type 1 diabetes (2013-22): a longitudinal analysis of data from paediatric diabetes registries","volume":"13","author":"Zimmermann","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"Suppl 1","key":"2026061619571680200_dgag164-B5","doi-asserted-by":"crossref","first-page":"S297","DOI":"10.2337\/dc26-S014","article-title":"14. Children and adolescents: standards of care in diabetes-2026","volume":"49","author":"American Diabetes Association Professional Practice Committee for Diabetes","year":"2026","journal-title":"Diabetes Care"},{"issue":"6","key":"2026061619571680200_dgag164-B6","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1159\/000543156","article-title":"International Society for Pediatric and Adolescent Diabetes clinical practice consensus guidelines 2024 diabetes technologies: glucose monitoring","volume":"97","author":"Tauschman","year":"2024","journal-title":"Horm Res Paediatr"},{"issue":"Suppl_1","key":"2026061619571680200_dgag164-B7","doi-asserted-by":"crossref","first-page":"S150","DOI":"10.2337\/dc26-S007","article-title":"7. Diabetes technology: standards of care in diabetes-2026","volume":"49","author":"American Diabetes Association Professional Practice Committee for Diabetes","year":"2026","journal-title":"Diabetes Care"},{"issue":"Suppl 2","key":"2026061619571680200_dgag164-B8","doi-asserted-by":"crossref","first-page":"S165","DOI":"10.1210\/clinem\/dgaf034","article-title":"Diabetes technology trends: a review of the latest innovations","volume":"110","author":"Lundgrin","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2026061619571680200_dgag164-B9","first-page":"537","article-title":"Continuous glucose monitoring in type 1 diabetes, type 2 diabetes, and diabetes during pregnancy: a systematic review with meta-analysis of randomized controlled trials","volume":"27","author":"Rizos","year":"2025","journal-title":"Diabetes Technol Ther"},{"issue":"1","key":"2026061619571680200_dgag164-B10","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1177\/26350106231220023","article-title":"Updating our understanding of device use in adolescents: demographic factors and preferences in a group of adolescents with type 1 diabetes","volume":"50","author":"Garretson","year":"2024","journal-title":"Sci Diabetes Self Manag Care"},{"issue":"5","key":"2026061619571680200_dgag164-B11","first-page":"768","article-title":"Early continuous glucose monitor use in children and adolescents with type 1 diabetes: rates of initiation and impact on glycemic outcomes","volume":"48","author":"Mann","year":"2025","journal-title":"Diabetes Care"},{"issue":"7","key":"2026061619571680200_dgag164-B12","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1038\/s41591-024-02975-y","article-title":"Equitable implementation of a precision digital health program for glucose management in individuals with newly diagnosed type 1 diabetes","volume":"30","author":"Prahalad","year":"2024","journal-title":"Nat Med"},{"issue":"3","key":"2026061619571680200_dgag164-B13","doi-asserted-by":"crossref","first-page":"750","DOI":"10.2337\/dc21-2004","article-title":"Continuous glucose monitoring initiation within first year of type 1 diabetes diagnosis is associated with improved glycemic outcomes: 7-year follow-up study","volume":"45","author":"Champakanath","year":"2022","journal-title":"Diabetes Care"},{"issue":"10","key":"2026061619571680200_dgag164-B14","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1056\/NEJMoa2203496","article-title":"Closed-loop therapy and preservation of C-peptide secretion in type 1 diabetes","volume":"387","author":"Boughton","year":"2022","journal-title":"N Engl J Med"},{"issue":"12","key":"2026061619571680200_dgag164-B15","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1001\/jama.2023.2063","article-title":"Effect of tight glycemic control on pancreatic Beta cell function in newly diagnosed pediatric type 1 diabetes: a randomized clinical trial","volume":"329","author":"McVean","year":"2023","journal-title":"JAMA"},{"issue":"2","key":"2026061619571680200_dgag164-B16","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1210\/clinem\/dgaf397","article-title":"Sustained HbA1c improvements over 36 months in youth in the teamwork, targets, technology, and tight control (4T) study","volume":"111","author":"Prahalad","year":"2026","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2026061619571680200_dgag164-B17","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S2213-8587(23)00061-X","article-title":"Continuous glucose monitoring versus blood glucose monitoring for risk of severe hypoglycaemia and diabetic ketoacidosis in children, adolescents, and young adults with type 1 diabetes: a population-based study","volume":"11","author":"Karges","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"23","key":"2026061619571680200_dgag164-B18","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1001\/jama.2020.6940","article-title":"Effect of continuous glucose monitoring on glycemic control in adolescents and young adults with type 1 diabetes: a randomized clinical trial","volume":"323","author":"Laffel","year":"2020","journal-title":"JAMA"},{"issue":"22","key":"2026061619571680200_dgag164-B19","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1001\/jama.2021.7444","article-title":"Effect of continuous glucose monitoring on glycemic control in patients with type 2 diabetes treated with basal insulin: a randomized clinical trial","volume":"325","author":"Martens","year":"2021","journal-title":"JAMA"},{"issue":"4","key":"2026061619571680200_dgag164-B20","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1089\/dia.2024.0579","article-title":"A randomized controlled trial using continuous glucose monitoring to guide food choices and diabetes self-care in people with type 2 diabetes not taking insulin","volume":"27","author":"Martens","year":"2025","journal-title":"Diabetes Technol Ther"},{"issue":"Suppl 1","key":"2026061619571680200_dgag164-B21","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.2337\/dc26-S002","article-title":"2. Diagnosis and classification of diabetes: standards of care in diabetes-2026","volume":"49","author":"American Diabetes Association Professional Practice Committee for Diabetes","year":"2026","journal-title":"Diabetes Care"},{"issue":"6","key":"2026061619571680200_dgag164-B22","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1159\/000543035","article-title":"ISPAD clinical practice consensus guidelines 2024: screening, staging, and strategies to preserve Beta-cell function in children and adolescents with type 1 diabetes","volume":"97","author":"Haller","year":"2024","journal-title":"Horm Res Paediatr"},{"issue":"8","key":"2026061619571680200_dgag164-B23","first-page":"1276","article-title":"Consensus guidance for monitoring individuals with islet autoantibody-positive Pre-stage 3 type 1 diabetes","volume":"47","author":"Phillip","year":"2024","journal-title":"Diabetes Care"},{"issue":"7","key":"2026061619571680200_dgag164-B24","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1902226","article-title":"An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes","volume":"381","author":"Herold","year":"2019","journal-title":"N Engl J Med"},{"issue":"23","key":"2026061619571680200_dgag164-B25","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1056\/NEJMoa2306691","article-title":"Baricitinib and beta-cell function in patients with new-onset type 1 diabetes","volume":"389","author":"Waibel","year":"2023","journal-title":"N Engl J Med"},{"issue":"9","key":"2026061619571680200_dgag164-B26","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.2337\/dc18-0494","article-title":"Low-dose anti-thymocyte globulin (ATG) preserves beta-cell function and improves HbA(1c) in new-onset type 1 diabetes","volume":"41","author":"Haller","year":"2018","journal-title":"Diabetes Care"},{"issue":"5","key":"2026061619571680200_dgag164-B27","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.2337\/db20-1103","article-title":"Low-dose ATG\/GCSF in established type 1 diabetes: a five-year follow-up report","volume":"70","author":"Lin","year":"2021","journal-title":"Diabetes"},{"key":"2026061619571680200_dgag164-B28","doi-asserted-by":"crossref","first-page":"506","DOI":"10.2337\/db25-0777","article-title":"Phase I clinical trial of islet antigen-specific plasmid coexpressing tolerogenic proteins demonstrates safety in adults with type 1 diabetes","volume":"75","author":"Greenbaum","year":"2026","journal-title":"Diabetes"},{"key":"2026061619571680200_dgag164-B29","doi-asserted-by":"publisher","DOI":"10.1177\/15209156251403551","article-title":"Antigen-specific chimeric antigen receptor-T regulatory cells home to human islets, suppress cytotoxic T lymphocytes and reverse type 1 diabetes","author":"Imam","journal-title":"Diabetes Technol Ther"},{"issue":"5","key":"2026061619571680200_dgag164-B30","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.2337\/dc22-2200","article-title":"Abatacept for delay of type 1 diabetes progression in stage 1 relatives at risk: a randomized, double-masked, controlled trial","volume":"46","author":"Russell","year":"2023","journal-title":"Diabetes Care"},{"issue":"23","key":"2026061619571680200_dgag164-B31","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1056\/NEJMoa2308743","article-title":"Teplizumab and beta-cell function in newly diagnosed type 1 diabetes","volume":"389","author":"Ramos","year":"2023","journal-title":"N Engl J Med"},{"issue":"4","key":"2026061619571680200_dgag164-B32","doi-asserted-by":"crossref","first-page":"528","DOI":"10.2337\/dc24-2376","article-title":"Repeated OGTT versus continuous glucose monitoring for predicting development of stage 3 type 1 diabetes: a longitudinal analysis","volume":"48","author":"Desouter","year":"2025","journal-title":"Diabetes Care"},{"issue":"6","key":"2026061619571680200_dgag164-B33","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1210\/clinem\/dgae691","article-title":"Discrimination and precision of continuous glucose monitoring in staging children with presymptomatic type 1 diabetes","volume":"110","author":"Huber","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2026061619571680200_dgag164-B34","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1007\/s00125-025-06362-1","article-title":"Continuous glucose monitor metrics from five studies identify participants at risk for type 1 diabetes development","volume":"68","author":"Calhoun","year":"2025","journal-title":"Diabetologia"},{"issue":"10","key":"2026061619571680200_dgag164-B35","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.2337\/dc24-0540","article-title":"Early dysglycemia is detectable using continuous glucose monitoring in very young children at risk of type 1 diabetes","volume":"47","author":"Haynes","year":"2024","journal-title":"Diabetes Care"},{"issue":"4","key":"2026061619571680200_dgag164-B36","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1177\/19322968251333441","article-title":"The use of continuous glucose monitoring to diagnose stage 2 type 1 diabetes","volume":"19","author":"Mader","year":"2025","journal-title":"J Diabetes Sci Technol"},{"issue":"11","key":"2026061619571680200_dgag164-B37","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1001\/jamapediatrics.2025.2740","article-title":"Automated insulin delivery systems and glucose management in children and adolescents with type 1 diabetes: a systematic review and meta-analysis","volume":"179","author":"de Visser","year":"2025","journal-title":"JAMA Pediatr"},{"issue":"12","key":"2026061619571680200_dgag164-B38","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.2337\/dc24-1313","article-title":"Eighteen-month hybrid closed-loop use in very young children with type 1 diabetes: a single-arm multicenter trial","volume":"47","author":"Ware","year":"2024","journal-title":"Diabetes Care"},{"issue":"8","key":"2026061619571680200_dgag164-B39","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.2337\/dc24-0360","article-title":"Effect of 48 months of closed-loop insulin delivery on residual C-peptide secretion and glycemic control in newly diagnosed youth with type 1 diabetes: a randomized trial","volume":"47","author":"Ware","year":"2024","journal-title":"Diabetes Care"},{"issue":"9","key":"2026061619571680200_dgag164-B40","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/j.eprac.2025.06.004","article-title":"A review of real-world evidence about the use of automated insulin delivery systems in people with type 1 diabetes","volume":"31","author":"Gera","year":"2025","journal-title":"Endocr Pract"},{"issue":"2","key":"2026061619571680200_dgag164-B41","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S2213-8587(24)00284-5","article-title":"Hybrid closed-loop insulin therapy and risk of severe hypoglycaemia and diabetic ketoacidosis in young people (aged 2-20 years) with type 1 diabetes: a population-based study","volume":"13","author":"Karges","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026061619571680200_dgag164-B42","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1177\/15209156251387160","article-title":"Automated insulin delivery is associated with reduced hospital admissions and costs for acute diabetes complications in children with type 1 diabetes","volume":"28","author":"Burnside","year":"2026","journal-title":"Diabetes Technol Ther"},{"issue":"14","key":"2026061619571680200_dgag164-B43","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1001\/jama.2017.13994","article-title":"Association of insulin pump therapy vs insulin injection therapy with severe hypoglycemia, ketoacidosis, and glycemic control among children, adolescents, and young adults with type 1 diabetes","volume":"318","author":"Karges","year":"2017","journal-title":"JAMA"},{"issue":"1","key":"2026061619571680200_dgag164-B44","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2400200","article-title":"Automated insulin delivery in older adults with type 1 diabetes","volume":"4","author":"Kudva","year":"2025","journal-title":"NEJM Evid"},{"issue":"4","key":"2026061619571680200_dgag164-B45","doi-asserted-by":"crossref","first-page":"648","DOI":"10.2337\/dc24-2483","article-title":"Association of diabetic ketoacidosis at onset, diabetes technology uptake, and clinical outcomes after 1 and 2 years of follow-up: a collaborative analysis of pediatric registries involving 9,269 children with type 1 diabetes from nine countries","volume":"48","author":"Dovc","year":"2025","journal-title":"Diabetes Care"},{"issue":"18","key":"2026061619571680200_dgag164-B46","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1056\/NEJMoa2415948","article-title":"A randomized trial of automated insulin delivery in type 2 diabetes","volume":"392","author":"Kudva","year":"2025","journal-title":"N Engl J Med"},{"issue":"10","key":"2026061619571680200_dgag164-B47","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.2337\/dc24-0626","article-title":"Empowering hospitalized patients with diabetes: implementation of a hospital-wide CGM policy with EHR-integrated validation for dosing insulin","volume":"47","author":"Lee","year":"2024","journal-title":"Diabetes Care"},{"issue":"2","key":"2026061619571680200_dgag164-B48","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2337\/dc24-1562","article-title":"Continuous glucose monitor accuracy for diabetes management in hospitalized children","volume":"48","author":"Garg","year":"2025","journal-title":"Diabetes Care"},{"issue":"19","key":"2026061619571680200_dgag164-B49","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1001\/jama.2024.18581","article-title":"GLP-1 Receptor agonist and SGLT2 inhibitor prescribing in people with type 1 diabetes","volume":"332","author":"Li","year":"2024","journal-title":"JAMA"},{"issue":"7","key":"2026061619571680200_dgag164-B50","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1038\/s41591-025-03723-6","article-title":"Adjunct-to-insulin therapy using SGLT2 inhibitors in youth with type 1 diabetes: a randomized controlled trial","volume":"31","author":"Mahmud","year":"2025","journal-title":"Nat Med"},{"issue":"1","key":"2026061619571680200_dgag164-B51","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1177\/19322968241291512","article-title":"Consensus report on glucagon-like peptide-1 receptor agonists as adjunctive treatment for individuals with type 1 diabetes using an automated insulin delivery system","volume":"19","author":"Shah","year":"2025","journal-title":"J Diabetes Sci Technol"},{"issue":"4","key":"2026061619571680200_dgag164-B52","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1038\/s41591-024-03463-z","article-title":"Subcutaneous weekly semaglutide with automated insulin delivery in type 1 diabetes: a double-blind, randomized, crossover trial","volume":"31","author":"Pasqua","year":"2025","journal-title":"Nat Med"},{"issue":"8","key":"2026061619571680200_dgag164-B53","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2500173","article-title":"Semaglutide in adults with type 1 diabetes and obesity","volume":"4","author":"Shah","year":"2025","journal-title":"NEJM Evid"},{"issue":"1","key":"2026061619571680200_dgag164-B54","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41746-018-0040-6","article-title":"Pivotal trial of an autonomous AI-based diagnostic system for detection of diabetic retinopathy in primary care offices","volume":"1","author":"Abramoff","year":"2018","journal-title":"NPJ Digit Med"},{"issue":"11","key":"2026061619571680200_dgag164-B55","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.34254","article-title":"Pivotal evaluation of an artificial intelligence system for autonomous detection of referrable and vision-threatening diabetic retinopathy","volume":"4","author":"Ipp","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"2","key":"2026061619571680200_dgag164-B56","first-page":"1","article-title":"Artificial intelligence systems for diabetic retinopathy screening: appraisal on the 3rd US FDA approved algorithms- AEYE-DS","volume":"4","author":"Vanessa","year":"2023","journal-title":"J Ophthalmol Adv Res"},{"issue":"8","key":"2026061619571680200_dgag164-B57","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1089\/dia.2024.0650","article-title":"Algorithm-driven initiation and adaptation of hybrid closed-loop in young children with type 1 diabetes: a pilot study","volume":"27","author":"Pavan","year":"2025","journal-title":"Diabetes Technol Ther"},{"issue":"1","key":"2026061619571680200_dgag164-B58","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1186\/s12887-025-05945-6","article-title":"Performance of several large language models when answering common patient questions about type 1 diabetes in children: accuracy, comprehensibility and practicality","volume":"25","author":"Ongen","year":"2025","journal-title":"BMC Pediatr"},{"key":"2026061619571680200_dgag164-B59","article-title":"Chat, Gemini and Claude at the dinner table: assessing general-purpose AI tools for carbohydrate counting in the context of type 1 diabetes","volume":"231","author":"Goncalves","year":"2025","journal-title":"Diabetes Res Clin Pract"},{"issue":"23","key":"2026061619571680200_dgag164-B60","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1001\/jama.2025.19563","article-title":"An AI-powered lifestyle intervention vs human coaching in the diabetes prevention program: a randomized clinical trial","volume":"334","author":"Mathioudakis","year":"2025","journal-title":"JAMA"},{"issue":"11","key":"2026061619571680200_dgag164-B61","doi-asserted-by":"crossref","DOI":"10.1111\/dme.70115","article-title":"The usability and feasibility of a self-compassion chatbot (COMPASS) for youth living with type 1 diabetes","volume":"42","author":"Boggiss","year":"2025","journal-title":"Diabet Med"},{"issue":"3","key":"2026061619571680200_dgag164-B62","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/s43588-024-00607-6","article-title":"Digital twins in medicine","volume":"4","author":"Laubenbacher","year":"2024","journal-title":"Nat Comput Sci"},{"issue":"1","key":"2026061619571680200_dgag164-B63","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/s41746-025-01679-y","article-title":"Human-machine co-adaptation to automated insulin delivery: a randomised clinical trial using digital twin technology","volume":"8","author":"Kovatchev","year":"2025","journal-title":"NPJ Digit Med"},{"issue":"1","key":"2026061619571680200_dgag164-B64","doi-asserted-by":"crossref","first-page":"39738","DOI":"10.1038\/s41598-025-23165-x","article-title":"A digital twin-enhanced decision support system improves time-in-range in type 1 diabetes: a randomized clinical trial","volume":"15","author":"Builes-Montano","year":"2025","journal-title":"Sci Rep"},{"issue":"1","key":"2026061619571680200_dgag164-B65","doi-asserted-by":"crossref","first-page":"25478","DOI":"10.1038\/s41598-024-76584-7","article-title":"One-year outcomes of a digital twin intervention for type 2 diabetes: a retrospective real-world study","volume":"14","author":"Shamanna","year":"2024","journal-title":"Sci Rep"},{"issue":"6","key":"2026061619571680200_dgag164-B66","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.jcjd.2016.04.010","article-title":"Techniques for exercise preparation and management in adults with type 1 diabetes","volume":"40","author":"Pinsker","year":"2016","journal-title":"Can J Diabetes"},{"issue":"7","key":"2026061619571680200_dgag164-B67","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.jcjd.2021.01.001","article-title":"Self-management group education to reduce fear of hypoglycemia as a barrier to physical activity in adults living with type 1 diabetes: a pilot randomized controlled trial","volume":"45","author":"Brennan","year":"2021","journal-title":"Can J Diabetes"},{"issue":"11","key":"2026061619571680200_dgag164-B68","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.2337\/dc08-0720","article-title":"Barriers to physical activity among patients with type 1 diabetes","volume":"31","author":"Brazeau","year":"2008","journal-title":"Diabetes Care"},{"issue":"2","key":"2026061619571680200_dgag164-B69","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s00125-024-06308-z","article-title":"The use of automated insulin delivery around physical activity and exercise in type 1 diabetes: a position statement of the European Association for the Study of Diabetes (EASD) and the International Society for Pediatric and Adolescent Diabetes (ISPAD)","volume":"68","author":"Moser","year":"2025","journal-title":"Diabetologia"},{"issue":"12","key":"2026061619571680200_dgag164-B70","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1007\/s00125-020-05263-9","article-title":"Glucose management for exercise using continuous glucose monitoring (CGM) and intermittently scanned CGM (isCGM) systems in type 1 diabetes: position statement of the European Association for the Study of Diabetes (EASD) and of the International Society for Pediatric and Adolescent Diabetes (ISPAD) endorsed by JDRF and supported by the American Diabetes Association (ADA)","volume":"63","author":"Moser","year":"2020","journal-title":"Diabetologia"},{"issue":"2","key":"2026061619571680200_dgag164-B71","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1089\/dia.2023.0376","article-title":"A randomized controlled trial assessing the impact of continuous glucose monitoring with a predictive hypoglycemia alert function on hypoglycemia in physical activity for people with type 1 diabetes (PACE)","volume":"26","author":"Rilstone","year":"2024","journal-title":"Diabetes Technol Ther"},{"key":"2026061619571680200_dgag164-B72","doi-asserted-by":"publisher","DOI":"10.1177\/19322968251361031","article-title":"Does continuous glucose monitoring use prompt greater engagement in self-management? A randomized controlled trial focusing on adults with type 2 diabetes","author":"Polonsky","journal-title":"J Diabetes Sci Technol"},{"issue":"11","key":"2026061619571680200_dgag164-B73","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.3390\/jcm10112445","article-title":"Time in range for closed-loop systems versus standard of care during physical exercise in people with type 1 diabetes: a systematic review and meta-analysis","volume":"10","author":"Eckstein","year":"2021","journal-title":"J Clin Med"},{"issue":"10","key":"2026061619571680200_dgag164-B74","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.2337\/dc25-0765","article-title":"Physical activity is associated with improved glycemic outcomes in newly diagnosed youth with type 1 diabetes: 4T exercise program","volume":"48","author":"Zaharieva","year":"2025","journal-title":"Diabetes Care"},{"key":"2026061619571680200_dgag164-B75","doi-asserted-by":"crossref","first-page":"16","DOI":"10.21037\/mhealth-24-63","article-title":"Evaluating the usability of Diactive-1: mHealth for personalized exercise and education in children and adolescents with type 1 diabetes","volume":"11","author":"Hormazabal-Aguayo","year":"2025","journal-title":"Mhealth"},{"issue":"2","key":"2026061619571680200_dgag164-B76","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/dom.15352","article-title":"Impact of a 4-week intensive track and field training intervention on glycaemia in adolescents with type 1 diabetes: the ChilDFiT1 study","volume":"26","author":"Zimmer","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"2026061619571680200_dgag164-B77","doi-asserted-by":"crossref","DOI":"10.2196\/51491","article-title":"Development of a novel mobile health app to empower young people with type 1 diabetes to exercise safely: co-design approach","volume":"9","author":"Shetty","year":"2024","journal-title":"JMIR Diabetes"},{"key":"2026061619571680200_dgag164-B78","doi-asserted-by":"crossref","DOI":"10.2196\/65665","article-title":"An exergames program for adolescents with type 1 diabetes: qualitative study of acceptability","volume":"10","author":"Mak","year":"2025","journal-title":"JMIR Diabetes"},{"issue":"9","key":"2026061619571680200_dgag164-B79","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1089\/dia.2025.0062","article-title":"Fully closed-loop improves glycemic control compared with pump with CGM in adolescents with type 1 diabetes and HbA1c above target: a two-center, randomized crossover study","volume":"27","author":"Kadiyala","year":"2025","journal-title":"Diabetes Technol Ther"},{"key":"2026061619571680200_dgag164-B80","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.2337\/dc21-0932","article-title":"Advanced closed-loop control system improves postprandial glycemic control compared with a hybrid closed-loop system following unannounced meal","volume":"44","author":"Garcia-Tirado","year":"2021","journal-title":"Diabetes Care"},{"key":"2026061619571680200_dgag164-B81","doi-asserted-by":"publisher","DOI":"10.1177\/15209156261423558","article-title":"Glycemic outcomes during outpatient use of automated insulin delivery without meal announcement in adults with type 1 diabetes: results from the CLOSE IT randomized controlled trial","author":"Wilkinson","journal-title":"Diabetes Technol Ther"},{"key":"2026061619571680200_dgag164-B82","doi-asserted-by":"publisher","DOI":"10.1177\/19322968251389966","article-title":"Fully closed-loop insulin delivery with high-carbohydrate and high-fat meals using the tandem freedom system","author":"Wilkinson","journal-title":"J Diabetes Sci Technol"},{"issue":"3","key":"2026061619571680200_dgag164-B83","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1089\/dia.2023.0380","article-title":"A comparison of continuous glucose monitoring-measured time-in-range 70-180 mg\/dL versus time-in-tight-range 70-140 mg\/dL","volume":"26","author":"Beck","year":"2024","journal-title":"Diabetes Technol Ther"},{"issue":"3","key":"2026061619571680200_dgag164-B84","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1089\/dia.2023.0602","article-title":"Is it time to replace time-in-range with time-in-tight-range? Maybe not","volume":"26","author":"Beck","year":"2024","journal-title":"Diabetes Technol Ther"},{"issue":"3","key":"2026061619571680200_dgag164-B85","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1089\/dia.2023.0565","article-title":"Is it time to move beyond TIR to TITR? Real-world data from over 20,000 users of continuous glucose monitoring in patients with type 1 and type 2 diabetes","volume":"26","author":"Dunn","year":"2024","journal-title":"Diabetes Technol Ther"},{"issue":"12","key":"2026061619571680200_dgag164-B86","doi-asserted-by":"crossref","DOI":"10.1111\/dme.15423","article-title":"\u2018We're taught green is good': perspectives on time in range and time in tight range from youth with type 1 diabetes, and parents of youth with type 1 diabetes","volume":"41","author":"Tanenbaum","year":"2024","journal-title":"Diabet Med"},{"key":"2026061619571680200_dgag164-B87","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.eprac.2025.03.006","article-title":"Moving the goalposts: do adults with type 1 diabetes want time in tight range (TITR)?","volume":"31","author":"Tanenbaum","year":"2025","journal-title":"Endocr Pract"},{"issue":"1","key":"2026061619571680200_dgag164-B88","doi-asserted-by":"crossref","first-page":"6","DOI":"10.2337\/dci24-0058","article-title":"Using time in tight glucose range as a health-promoting strategy in preschoolers with type 1 diabetes","volume":"48","author":"Sundberg","year":"2025","journal-title":"Diabetes Care"},{"issue":"7","key":"2026061619571680200_dgag164-B89","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.2337\/dc25-0129","article-title":"A comparative analysis of glycemic metrics derived from three continuous glucose monitoring systems","volume":"48","author":"Freckmann","year":"2025","journal-title":"Diabetes Care"},{"key":"2026061619571680200_dgag164-B90","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1111\/dom.70460","article-title":"International clinical opinion on transparency, standardisation, and calibration alignment in the performance evaluation of systems for continuous glucose monitoring","volume":"28","author":"Pemberton","year":"2026","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"2026061619571680200_dgag164-B91","doi-asserted-by":"crossref","DOI":"10.1111\/dme.70007","article-title":"Marked improvement in HbA1c following introduction of biosimilar insulin to treatment regimen of children and youth with type 1 diabetes in Mali: a randomised controlled trial","volume":"42","author":"Besancon","year":"2025","journal-title":"Diabet Med"},{"issue":"8","key":"2026061619571680200_dgag164-B92","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.28933","article-title":"Global inequities in diabetes technology and insulin access and glycemic outcomes","volume":"8","author":"Santova","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"1","key":"2026061619571680200_dgag164-B93","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2337\/dc20-0257","article-title":"A decade of disparities in diabetes technology use and HbA(1c) in pediatric type 1 diabetes: a transatlantic comparison","volume":"44","author":"Addala","year":"2021","journal-title":"Diabetes Care"},{"issue":"11","key":"2026061619571680200_dgag164-B94","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1089\/dia.2023.0320","article-title":"Longitudinal trends in glycemic outcomes and technology use for over 48,000 people with type 1 diabetes (2016-2022) from the T1D exchange quality improvement collaborative","volume":"25","author":"Ebekozien","year":"2023","journal-title":"Diabetes Technol Ther"},{"issue":"7","key":"2026061619571680200_dgag164-B95","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvaf068","article-title":"Determining insulin pump candidacy: the disconnect between clinical care guidelines and clinical practice","volume":"9","author":"Everett","year":"2025","journal-title":"J Endocr Soc"},{"issue":"4","key":"2026061619571680200_dgag164-B96","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.8881","article-title":"Disparities in hemoglobin A1c levels in the first year after diagnosis among youths with type 1 diabetes offered continuous glucose monitoring","volume":"6","author":"Addala","year":"2023","journal-title":"JAMA Netw Open"},{"key":"2026061619571680200_dgag164-B97","doi-asserted-by":"crossref","DOI":"10.2196\/71038","article-title":"Implementation and evaluation of a best practice advisory to reduce inequities in technology use for people with type 1 diabetes: protocol for a mixed methods, nonrandomized controlled trial","volume":"14","author":"Mathioudakis","year":"2025","journal-title":"JMIR Res Protoc"},{"key":"2026061619571680200_dgag164-B98","volume-title":"Sanofi's Tzeild Approved in the EU for Patients with Stage 2 Type 1 Diabetes","author":"Sanofi","year":"2026"},{"issue":"2","key":"2026061619571680200_dgag164-B99","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S2213-8587(22)00384-9","article-title":"Teplizumab approval for type 1 diabetes in the USA","volume":"11","author":"Beran","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"S4","key":"2026061619571680200_dgag164-B100","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1177\/15209156251390818","article-title":"Clinical trials in diabetes: examining the value of use of continuous dual glucose-ketone monitoring","volume":"27","author":"Akturk","year":"2025","journal-title":"Diabetes Technol Ther"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgag164\/68066761\/dgag164.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/111\/7\/e1739\/68066761\/dgag164.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/111\/7\/e1739\/68066761\/dgag164.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T23:57:33Z","timestamp":1781654253000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/111\/7\/e1739\/8653115"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,13]]},"references-count":100,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,4,13]]},"published-print":{"date-parts":[[2026,6,17]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgag164","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,4,13]]}}}